Safety Alerts Saves Lives
Safety Alerts  
Home Privacy About Us Contact Us Change Preferences
spacer.gif (43 bytes)
December 12,  2001

International Study Validates Effectiveness of Aldara™ for Treating Sexually Transmitted Disease


 (SafetyAlerts) - New findings from a recent, international, open-label study reaffirm that the patient-applied treatment, Aldara™ (imiquimod) Cream, 5%, is safe and effective for eradicating external genital warts – the results of which are reflective of a real-life clinic setting.1

The study reports that the efficacy of Aldara in 943 male and female patients of different ethnic backgrounds was similar to that in previous randomized, vehicle-controlled studies, according to the International Journal of STD & AIDS. 1,2,3

This international trial is the first published study that investigates the efficacy of a topical therapy for external genital warts in such a large group of patients - in 114 clinics across five continents (Europe, Canada, Latin America, Australia and South Africa).1

Patients whose warts decreased in size but did not totally clear in the initial 16 weeks of therapy (191, 20%), were offered the option to apply Aldara for up to an additional 16 weeks. This resulted in total clearance in 33 percent of these patients.

This continued application of Aldara was well-tolerated by patients, and this study highlights that the frequency of application site reactions was, indeed, lower in the second treatment cycle compared to the initial 16 weeks of therapy.

Furthermore, the results of this study validate previous observations from the highly controlled trials that patients whose warts cleared with Aldara therapy, tended to remain clear.2,3

‘The fact that less than 10 percent of the patients required re-treatment in the 3 months after their warts cleared, is a considerable advantage of this cream compared to many of the other genital wart treatments that are available,’ comments lead author Dr Suzanne Garland, Department of Microbiology and Infectious Diseases, Royal Women’s and Royal Children’s Hospitals, Victoria, Australia.

For patients whose warts did return, doctors advised them to apply Aldara for up to an additional 16 weeks. This was reported to be as equally effective as when Aldara was first applied, with total clearance observed in 70 percent of those patients.1

A low rate of recurrence after treatment is an important factor in the successful management of external genital warts, as it is likely to decrease the number of clinic visits a patient makes for repeat treatment.

Genital warts, caused by human papillomavirus, are one of the most common sexually transmitted diseases. By one estimate, at least 10 percent of sexually active adults in the US are infected with HPV, with perhaps 1-2 percent having genital warts.4 The incidence of genital warts is greatest in young adults between 18 and 28 years of age.1.

Source: PRNewswire.

Selected Recent Recalls

Health Professional:

Did you know?
During 2000 there were over
1050 products recalled in the United
States for safety reasons!

How many did you hear about?

Sign-up for SafetyAlerts by Email -
The free internet newsletter that could
some day literally save your life - or
the life of someone you know.


The information contained herein has been obtained from sources that the Company believes to be reliable, however, the Company has not independently verified or confirmed the information and the recipient acknowledges that no representations or warranties are being made in connection with the use of the information.